首页> 外文期刊>Allergy >One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: Review of unanswered questions
【24h】

One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: Review of unanswered questions

机译:过敏原免疫疗法一百周年欧洲过敏与临床免疫学学会庆祝:未回答问题的复习

获取原文
获取原文并翻译 | 示例
           

摘要

Allergen immunotherapy was introduced by Leonard Noon 100 years ago and is the only disease-modifying treatment for allergic individuals. Improved understanding of immunology has taught us a great deal about the underlying mechanisms involved in allergen immunotherapy; however, despite these developments, a number of important questions remain unanswered. Several of these questions relate to the practice of allergen immunotherapy in the clinic, such as: Is it possible to unify units of allergen potency? Which treatment schedules are best? Is allergen immunotherapy effective in all patient groups? Is there a dose-response relationship for efficacy and safety?, and Is there evidence for long-term effects following allergen immunotherapy? Others are related to new developments, such as new indications, or developments in the production of allergens. On the centenary of Noon's discovery, European experts in the field of immunotherapy met in Geneva under the aegis of the EAACI to discuss these controversial issues. This study presents outcomes and conclusions from these discussions.
机译:变应原免疫疗法是伦纳德·诺恩(Leonard Noon)于100年前提出的,它是唯一针对变态反应性个体的疾病缓解疗法。对免疫学的进一步了解使我们了解了有关变应原免疫疗法的基本机制。然而,尽管有这些发展,但许多重要问题仍未得到解答。这些问题中有几个与临床上的变应原免疫疗法有关,例如:是否可以统一变应原效力单位?哪种治疗方案最好?过敏原免疫疗法在所有患者组中均有效吗?疗效和安全性是否存在剂量反应关系?过敏原免疫治疗后是否有长期作用的证据?其他与新发展有关,例如新适应症或过敏原生产中的发展。在正午发现一百周年之际,欧洲免疫治疗领域的专家在EAACI的支持下在日内瓦开会,讨论了这些有争议的问题。这项研究提出了这些讨论的结果和结论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号